Osl asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar.

Morningstar Investor users sign in here. Skip to Content. Market Centre. United States. Market Report. ASX Market Report. Roundup of ASX market movements.

Osl asx

OncoSil Medical Limited. Is OSL undervalued compared to its fair value, analyst forecasts and its price relative to the market? For this estimate we use a Discounted Cash Flow model. This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors. What is the analyst month forecast and do we have any statistical confidence in the consensus price target? Analyst Forecast: Insufficient data to show price forecast. View Company Overview. Share Price vs Fair Value. Key Valuation Metric. Other financial metrics that can be useful for relative valuation. This is calculated by dividing OSL's market cap by their current preferred multiple.

Investing content.

At OncoSil Medical, we are committed to making a positive change through the dedication and compassion of our team. This is why it is important that you get to know the people behind the logo. At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings.

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US. Show more Companies link Companies. Show more Tech link Tech.

Osl asx

OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. Financial Times Close. Search the FT Search. Show more World link World. Show more US link US.

Do walmart do afterpay

You might already have an ASX account with another platform. Market Calendar. Save Clear. Dec Morningstar Investment Management. Analytics Analytics. Industry Insights. Functional Functional. Market data is provided and copyrighted by Thomson Reuters and Morningstar. In his year career at Sirtex, Nigel has held several executive roles across different regions globally while focusing on business leadership, corporate development, strategic licensing agreements with third parties, mergers and acquisitions and sales management. He has spent the past 30 years in scientific affairs and marketing with a significant emphasis on oncology.

Key events shows relevant news articles on days with large price movements.

Public consultations. To benefit from this content, plus our exclusive data archive, subscribe to the FT today. We also use third-party cookies that help us analyze and understand how you use this website. Subscribe to the FT now. Check our help guide for more info. Haven't signed up? Goals based portfolio construction. Confirm password. Prior to joining OncoSil, Nicole was a Global Regulatory Affairs Manager at Sirtex Medical, focusing on preparation and maintenance of international product registrations for their brachytherapy device. Use our equities screener to discover other potential opportunities. Save Clear.